机构：[1]Key Laboratory of Head and Neck Molecular Diagnosis Pathology, Department of Pathology, Beijing TongRen Hospital, Capital Medical University, Beijing, China医技科室病理科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[2]Department of Pathology, Cangzhou People’s Hospital, Cangzhou, China[3]Department of Obstetrics, Cangzhou People’s Hospital, Cangzhou, China[4]Department of Radiotherapy, Cangzhou People’s Hospital, Cangzhou, China
This study was funded by Beijing municipal education commission
(N. KZ201910025033); Beijing municipal administration of Hospitals
clinical medicine development of Special Funding (N. ZYLX201814);
2021 Medical Scientific Research Project Plan of Hebei Province (grant
N.20211171).
第一作者机构：[1]Key Laboratory of Head and Neck Molecular Diagnosis Pathology, Department of Pathology, Beijing TongRen Hospital, Capital Medical University, Beijing, China[2]Department of Pathology, Cangzhou People’s Hospital, Cangzhou, China
通讯作者：
通讯机构：[1]Key Laboratory of Head and Neck Molecular Diagnosis Pathology, Department of Pathology, Beijing TongRen Hospital, Capital Medical University, Beijing, China[*1]Key Laboratory of Head and Neck Molecular Diagnosis Pathology, Department of Pathology, Beijing TongRen Hospital, Capital Medical University, Dongjiaomin Lane 1, 100005 Beijing, China
推荐引用方式(GB/T 7714)：
Ma Hongyan,Shi Shuai,Ma Zhihong,et al.ADORA2B facilitates cervical carcinoma progression by maintaining PD-L1 expression through master regulator CMTM6[J].Panminerva Medica.2024,doi:10.23736/S0031-0808.24.05152-8.
APA：
Ma Hongyan,Shi Shuai,Ma Zhihong,Niu Shulei,Liu Xiaoyun...&Liu Honggang.(2024).ADORA2B facilitates cervical carcinoma progression by maintaining PD-L1 expression through master regulator CMTM6.Panminerva Medica,,
MLA：
Ma Hongyan,et al."ADORA2B facilitates cervical carcinoma progression by maintaining PD-L1 expression through master regulator CMTM6".Panminerva Medica .(2024)
